Joint Symptoms, Aromatase Inhibitor-Related Adverse Reactions, Are Indirectly Associated with Decreased Serum Estradiol

Table 2

Clinical parameters of patients with joint symptoms and without joint symptoms (𝑛=104).

		With joint Symptoms; 𝑛=33	Without joint symptoms; 𝑛=71	P value of chi square tests	Univariate Analysis^a		Multivariate Analysis^a
					Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
Age (years)	<55; 55–65; 65≤	5; 19; 9	3; 34; 34	𝑃<.05	0.43 (0.21–0.86)	<.05	0.47 (0.21–1.05)	NS
Age at menarche (years)	<12; 12–15; 15≤	2; 30; 1	3; 57; 11	NS	0.37 (0.11–1.21)	NS
No. of childbirths	None; 1-2; 2≤	2; 24; 7	8; 21; 42	NS	1.14 (0.54–2.41)	NS
BMI (kg/m^2)	<25; 25–30; 30≤	18; 13; 2	44; 21; 6	NS	1.13 (0.60–2.15)	NS
Therapy prior to AI administration	None; Yes	18; 15	48; 23	NS	Not analyzed^b
Time from menopause^c (years)	<5; 5–10; 10≤	8; 11; 14	8; 21; 42	NS; 𝑃=.056; (<5 ver 10≤)	0.59 (0.34–1.02)	.059
Pre-AI administration %YAM (%)	<70; 70–80; 80≤	6; 12; 12	25; 30; 12	NS	1.98 (1.09–3.61)	<.05	1.65; (0.84 – 3.21)	NS
Pre-AI administration %AGE (%)	<80; 80–100; 100≤	4; 11; 15	10; 31; 27	NS	1.28 (0.68–2.39)	NS
Change of E2	Rebound; Decreased	0; 33	8; 63	𝑃<.05	2.52 (1.01–6.26)	<.05	2.28; (0.70 – 7.40)	NS
Change of T-chol^d	Elevated; Non-elevated	16; 13	15; 49	𝑃<.05	0.30 (0.13–0.71)	<.01	0.52; (0.22 – 1.25)	NS
Change of %AGE^d	Not -decreased; Decreased	17; 13	44; 22	NS	1.63 (0.70–3.77)	NS

BMI: body mass index; AI: aromatase inhibitor; %YAM: % young adult mean value; %AGE: % age-matched mean value; E2: estradiol; T-chol: total cholesterol;　 NS: not significance. ^aMaltivariate logistic regression analysis (trend analysis). ^bBecause of the diversity of the treatment methods employed, statistical analyses were not performed. ^cTime from menopause until AI administration. ^dExcluded patients with medicine.